No Data
Express News | Allarity Therapeutics Inc - Two Patients Exceed 14 Months on Treatment in Phase 2 Trial
Express News | Allarity Therapeutics Inc - Maintains Cash Balance of $18.5 Million
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Allarity Therapeutics | 10-Q: Q3 2024 Earnings Report
Allarity Therapeutics Q3 EPS $(7.71) Beats $(8.40) Estimate
Express News | Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
No Data
No Data